Protective effects of candesartan cilexetil (TCV-116) against stroke, kidney dysfunction and cardiac hypertrophy in stroke-prone spontaneously hypertensive rats

Clinical and Experimental Hypertension

Volumn 19, Issue 7, 1997, Pages 1079-1099

  Inada, Y ^a   Wada, T ^a   Ojima, M ^a   Sanada, T ^a   Shibouta, Y ^a   Kanagawa, R ^a   Ishimura, Y ^a   Fujisawa, Y ^a   Nishikawa, K ^a  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

Candesartan cilexetil; Enalapril; Organ damages; Renal mRNA; Renin angiotensin system; Stroke prone spontaneously hypertensive rats(SHRSP); TCV 116

Indexed keywords

CANDESARTAN HEXETIL; ENALAPRIL;

ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; HEART VENTRICLE HYPERTROPHY; HYPERTENSION; KIDNEY DISEASE; MALE; NONHUMAN; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SPONTANEOUSLY HYPERTENSIVE RAT; STROKE;

EID: 0030800377     PISSN: 10641963     EISSN: None     Source Type: Journal    
DOI: 10.3109/10641969709083206     Document Type: Article

References (54)

1. Veterans Administration Cooperative Study Group on Antihypertensive Agents: Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressure averaging 115 through 129 mmHg. JAMA. 1967; 202: 1028-1034.
2. Veterans Administration Cooperative Study Group on Antihypertensive Agents: Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mmHg. JAMA. 1970; 213: 1143-1152.
3. Amery, A., Brixko, P., Clement, D., De Schaepdryver, A., Fagard, R., Forte, J., Henry, J.F., Leonetti, G., O'Malley, K., Strasser, J., Birkenhager, W., Bulpitt, C., Deruxttere, M., Dollery, C., Forette, F., Hamdy, R., Joossens, J.V., Load-Johansen, P., Petrie, J., Tuomilehto, J.: Mortality and morbidity result from the European Working Party on High Blood Pressure in the Elderly trial. Lancet. 1985; i: 1349-1354.
4. Medical Research Council Working Party: MRC trial of treatment of mild hypertension: principal results. Br Med J. 1985; 291: 97-104.
5. The IPPPSH Collaborative Group: Cardiovascular risk and risk factors in a randomized trial of treatment based on the beta-blocker oxprenolol: the International Prospective Primary Prevention Study in Hypertension (IPPPSH). J Hypertens. 1985; 3: 379-392.
6. Okamoto, K., Yamori, Y., Nagaoka, A.: Establishment of the stroke-prone spontaneously hypertensive rat (SHR). Circ Res. 1974; 34/35 (suppl 1):1-143-1-145.
7. Yamori, Y., Horie, R., Sato, M., Handa, H., Fukasa, M.: Pathogenic similarity of stroke in stroke-prone SHR and humans. Stroke. 1976; 7: 46-53.
8. Shibota, M., Nagaoka, A., Shino, A., Fujita, T.: Renin-angiotensin system in stroke-prone spontaneously hypertensive rats. Am J Physiol. 1979; 236: H409-H416.
9. Stier, C.T, Jr, Benter, I.F., Ahmad, S., Zuo, H., Selig, N., Roethel, S., Levine, S., Itskovitz, H.D.: Enalapril prevents stroke and kidney dysfunction in salt-loaded stroke-prone spontaneously hypertensive rats. Hypertension. 1989; 13: 115-121.
10. Watanabe, T., Kawashima, K., Sokabe, H.: Chronic effects of enalapril on blood pressure, stroke, plasma renin, urinary electrolytes and PGE2 excretion in stroke-prone spontaneously hypertensive rats. Jpn J Pharmacol. 1985; 38: 419-427.
11. Baranes, J., Hegarat, L.M.E., Thievant, P., Siou, G.: Beneficial effects of cicletanide in stroke-prone hypertensive rats. (abstract) Prostaglandins. 1984; 27(suppl): s71.
12. Inada, Y., Itoh, K., Ojima, M., Shino, A., Nishikawa, K.: Delapril prevents stroke, renal dysfunction and cardiac hypertrophy in stroke prone spontaneously hypertensive rats. Jpn Pharmacol Ther. 1990; 18: 2199-2209.
13. Hajdu, M.A., Heistad, D.D., Baumbach, G.L.: Effects of antihypertensive therapy on mechanics of cerebral arterioles in rats. Hypertension. 1991; 17: 308-316.
14. Ogiku, N., Sumikawa, H., Hashimoto, Y., Ishida, R., : Prophylactic effect of imidapril of stroke in stroke-prone spontaneously hypertensive rats. Stroke. 1993, 24;245-252.
15. Masson, G.M.C., Corcoran, A.C., Page, I.H.: Renal and vascular lesions in rats with deoxycorticosterone hypertension. Arch Pathol. 1952; 53:217-225.
16. Masson, G.M.C., Mikasa, A., Yasuda, H.: Experimental vascular disease caused by aldosterone and renin. Endocrinology. 1962. 71: 505-512.
17. Masson, G.M.C., Kashii, C., Matsunaga, M., Page, I.H.: Hypertensive vascular disease produced by homologous renin. Science. 1964; 145: 178-180.
18. Gavras, H., Lever, A.F., Brown, J.J., Macadam, R.F., Robertson, I.J.: Acute renal failure, tubular necrosis and myocardial infarction induced in the rabbit by intravenous angiotensin II. Lancet. 1971; ii: 19-22.
19. Brunner, H.R., Laragh, J.H., Baer, L., Newton, M.A., Goodwin, F.T., Krakoff, L.R., Bard, R.H., Buhler, F.R.: Essential hypertension: renin -and aidosterone, heart attack and stroke. N Engl J Med. 1972; 286: 441-449.
20. Laragh, J.H., Baer, L., Brunner, H.R., Buhler, F.R., Sealey, J.E., Vaughan, E.D. Jr.: Renin, angiotensin and aldosterone system in pathogenesis and management of hypertensive vascular disease. Am J Med. 1972; 52: 633-652.
21. Volpe, M., Camargo, M.J.F., Mueller, F.B., Campbell, W.G. Jr., Sealey, J.E., Pecker, M.S., Sosa, R.E., Laragh, J.H.: Relation of plasma renin to end organ damage and to protection of K feeding in stroke-prone hypertensive rats. Hypertension. 1990; 15: 318-326.
22. Alderman, M.H., Madhavan, S., Ooi, W.L., Cohen, H., Sealey, J.E., Laragh, J.H.: Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med. 1991; 324: 1098-1104.
23. Kubo, K., Kohara, Y., Yoshimura, Y., Inada, Y., Shibouta, Y., Furukawa, Y., Kato, T., Nishikawa, K., Naka, T.: Nonpeptide angiotensin II receptor antagonists. Synthesis and biological activity of potential prodrugs of benzimidazole-7-carboxylic acids. J. Med. Chem. 1993; 36: 2343-2349.
24. Shibouta, Y., Inada, Y., Ojima, M., Wada, T., Noda, M., Sanada, T., Kubo, K., Kohara, Y., Naka, T., Nishikawa, K.: Pharmacological profile of a highly potent and long-acting angiotensin H receptor antagonist, 2-ethoxy-1-[[2′-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1 H-benzimidazole-7-carboxylic acid (CV-11974) and its prodrug, (±)-1-(cyclohexyloxycarbonyloxy)-ethyl 2-ethoxy-1-[[2′-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-benzimidazole- 7-carboxylate (TCV-116). J Pharmacol Exp Ther. 1993; 266: 114-120.
25. Noda, M., Shibouta, Y., Inada, Y., Ojima, M., Wada, T., Sanada, T., Kubo, K., Kohara, Y., Naka, T., Nishikawa, K.: Inhibition of rabit aortic angiotensin II (AII) receptor by CV-11974, a new nonpeptide AII antagonist. Biochem Pharmacol. 1993; 46: 311-318.
26. Inada, Y., Wada, T., Shibouta, Y., Ojima, M., Sanada, T., Ohtsuki, K., Itoh, K., Kubo, K., Kohara, Y., Naka, T., Nishikawa, K.: Antihypertensive effects of a highly potent and long acting angiotensin II subtype-1 receptor antagonist, (±) - 1 -(cyclohexyloxycarbonyloxy) ethyl 2 - ethoxy -1 - [[2′- (1 H-tetrazol-5-yl) biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylate (TCV-116), in various hypertensive rats. J Pharmacol Exp Ther. 1994; 268: 1540-1547.
27. Ito, K., Shiomi, M., Kito, G.: Effects of the non-peptide angiotensin II receptor antagonist TCV-116 on systemic and renal hemodynamics in dogs with renal hypertension. Hypertens Res. 1995; 18: 69-75.
28. Wada, T., Kanagawa, R., Ishimura, Y., Inada, Y., Nishikawa, K.: Role of angiotensin II in cerebrovascular and renal damage in deoxycorticosterone acetate-salt hypertensive rats. J Hypertens. 1995; 13: 113-122.
29. Inada, Y., Terashita, Z., Shibouta, Y., Nishikawa, K., Shino, A., Kikuchi, S., Shimamoto, K.: Acceleration of hypertension and development of stroke in the spontaneously hypertensive rat by unilateral ureteral obstruction. Clin Exp Hypertens. 1980; 2: 139-152.
30. Iwai, N., Inagami, T.: Quantitative analysis of renin gene expression in extrarenal tissues by polymerase chain reaction method. J Hypertens. 1992; 10: 717-724.
31. Dostal, D.E., Rothblum, K.N., Chemin, M.I., Cooper, G.R., Baker, K.M.: Intracardiac detection of angiotensinogen and renin: a localized renin-angiotensin system in neonatal rat heart. Am J Physiol. 1992; 263: C838-C850.
32. Makita, N., Iwai, N., Inagami, T., Badr, K.F.: Two distinct pathways in the down-regulation of type-1 angiotensin II receptor gene in rat glomerular mesangial cells. Biochem Biophys Res Commun. 1992; 185: 142-146.
33. Kitami, Y., Okura, T., Marumoto, K., Wakamiya, R., Hiwada, K.: Differential gene expression and regulation of type-1 angiotensin II receptor subtype in the rat. Biochem Biophys Res Commun. 1992; 188: 446-452.
34. Nagaoka, A., Iwatsuka, H., Suzuoki, Z., Okamoto, K.: Genetic predisposition to stroke in spontaneously hypertensive rats. Am J Physiol. 1976; 230: 1354-1359.
35. Matsunaga, M., Yamamoto, J., Hara, A., Yamori, Y., Ogino, K., Okamoto, K.: Plasma renin and hypertensive vascular complications: an observation in the stroke-prone spontaneously hypertensive rats. Jpn. Circ. J. 1975; 39: 1305-1311.
36. Laffan, R.J., Goldberg, M.E., High, J.P., Schaeffer, T., Waugh, M.H., Rubin, B.: Antihypertensive activity in rats of SQ14.225, an orally active inhibitor of angiotensin I-converting enzyme. J Pharmacol Exp Ther. 1978; 204: 281-288.
37. Sweet, C.S., Gross, D.M., Arbegast, P.T., Gaul, S.L., Britt, P.M., Ludden, C.T., Weitz, D., Stone, C.A.: Antihypertensive activity of N-[(s)-1-(ethoxycarbonyl)-3-phenylpropyl]-L-Ala-L-Pro (MK-421), an orally active converting enzyme inhibitor. J Pharmacol Exp Ther. 1981; 216: 558-566.
38. Inada, Y., Tanabe, M., Shibouta, Y., Kawazoe, K., Nishikawa, K., Kikuchi, S.: Antihypertensive action of a non-sulfhydryl angiotensin converting enzyme inhibitor (CV-3317) in various hypertensive models. Jpn J Pharmacol. 1986; 42: 1-8.
39. Unger, T., Yukimura, T., Marin-Grez, M., Lang, R.E., Rascher, W., Ganten, D.: SA446, a new oralfy active converting enzyme inhibitor: antihypertensive action and comparison with captopril in stroke-prone spontaneously hypertensive rats. Eur J Pharmacol. 1982; 78: 411-420.
40. Kawashima, K., Kimura, M., Watanabe, TX., Sokabe, H., Kobayashi, Y.: Effects of enalapril and captopril on urinary excretion of kinins and electrolytes in stroke-prone spontaneously hypertensive rats. Jpn J Pharmacol. 1985; 39: 415-417.
41. Moursi, M.G., Ganten, D., Lang, R.E., Unger, T.: Antihypertensive action and inhibition of tissue converting enzyme (CE) by three prodrug CE inhibitors, enalapril, ramipril and perindopril in stroke-prone spontaneously hypertensive rats. J Hypertens. 1986; 4 (Suppl. 3): S495.
42. Cohen, M.L., Kurz, K.D.: Angiotensin converting enzyme inhibition in tissue from spontaneously hypertensive rats after treatment with captopril or MK-421. J Pharmacol Exp Ther. 1982; 220: 63-69.
43. Miyazaki, M., Okunishi, H., Nishimura, K., Toda, N.: Vascular angiotensin-converting enzyme activity in man and other species. Clin Sci. 1984; 66: 39-45.
44. Unger, T., Ganten, D., Lang, R.E.: Converting enzyme inhibitors: antihypertensive drugs with unexpected mechanisms. Trends Pharmacol Sci. 1983; 4: 514-519.
45. Navar, L.G., Langford, H.G.: Effects of angiotensin on the renal circulation. In: Page IH, Bumpus FM (eds) Angiotensin. Springer-Verlag, New York, 1974, p. 455.
46. Clozel, J.-P., Hefti, F.: Cilazapril prevents the development of cardiac hypertrophy and the decrease of coronary vascular reserve in spontaneously hypertensive rats. J Cardiovasc Pharmacol. 1988; 11: 568-572.
47. Pfeffer, J.M., Pfeffer, M.A., Mirsky, I., Braunwald, E.: Regression of left ventricular hypertrophy and prevention of left ventricular dysfunction by captopril in the spontaneously hypertensive rat. Proc Natl Acad Sci. USA. 1989; 79: 3310-3314.
48. Sen, S., Tarazi, C.: Regression of myocardial hypertrophy and influence of adrenergic system. Am J Physiol. 1983; 244: H97-H101.
49. Linz, W., Scholkens, B.A., Ganten, D.: Converting enzyme inhibition specifically prevents the development and induces regression of cardiac hypertrophy. Clin Exp Hypertens. 1989; 11: 1325-1350.
50. Kannel, W.B., Castelli, W.P., McNamara, P.M., McKee, P.A., Fenleib, M.: Role of blood pressure in the development of congestive heart failure. The Framingham Study. N Engl J Med. 1972; 287: 781-787.
51. Campbell, D.J., Lawrence, A.C., Towrie, A., Kladis, A., Valentiju, A.J.: Differential regulation of angiotensin peptide levels in plasma and kidney of the rat Hypertension. 1991; 18: 763-773.
52. Mento, P.F., Wilkes, B.M.: Plasma angiotensins and blood pressure during converting enzyme inhibition. Hypertension. 1987; 9 [Suppl III]: 42-48.
53. Urata, H., Healy, B., Stewart, RW., Bumpus, FM, Husain, A.: Angiotensin II-forming pathways in normal and failing human hearts. Circ Res. 1990; 60:883-890.
54. Okamura, T., Okunishi, H., Ayajiki, K. and Toda, N.: Conversion of angiotensin I to angiotensin H in dog isolated renal artery: role of two different angiotensin II-generating enzymes. J Cardiovasc Pharmacol. 1990; 15:353-359.